Checkpoint Capital
Latest statistics and disclosures from Checkpoint Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RYTM, ARGX, CYTK, AVDL, AXSM, and represent 69.36% of Checkpoint Capital's stock portfolio.
- Added to shares of these 10 stocks: CORT (+$6.9M), AVDL (+$6.4M), ARGX, RYTM, MIRM, VSTM, APLT, PHAT, ATRA, ALLK.
- Started 4 new stock positions in VSTM, ATRA, APLT, CORT.
- Reduced shares in these 10 stocks: , SWTX (-$12M), IRWD (-$6.6M), CYTK, TRVI, AXSM, GHRS, IRON, ACRS, EWTX.
- Sold out of its positions in ACRS, IRON, EWTX, XBI, SWTX.
- Checkpoint Capital was a net seller of stock by $-14M.
- Checkpoint Capital has $150M in assets under management (AUM), dropping by -9.37%.
- Central Index Key (CIK): 0001977548
Tip: Access up to 7 years of quarterly data
Positions held by Checkpoint Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Checkpoint Capital
Checkpoint Capital holds 17 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals (RYTM) | 23.9 | $36M | +13% | 826k | 43.33 |
|
| Argenx Se Sponsored Adr (ARGX) | 21.6 | $32M | +17% | 82k | 393.72 |
|
| Cytokinetics Com New (CYTK) | 8.9 | $13M | -17% | 190k | 70.11 |
|
| Avadel Pharmaceuticals Sponsored Adr (AVDL) | 7.9 | $12M | +115% | 701k | 16.89 |
|
| Axsome Therapeutics (AXSM) | 7.1 | $11M | -14% | 132k | 79.80 |
|
| Mirum Pharmaceuticals (MIRM) | 6.1 | $9.1M | +55% | 362k | 25.12 |
|
| Protagonist Therapeutics (PTGX) | 5.4 | $8.1M | +5% | 280k | 28.93 |
|
| Corcept Therapeutics Incorporated (CORT) | 4.6 | $6.9M | NEW | 274k | 25.19 |
|
| Ironwood Pharmaceuticals Com Cl A (IRWD) | 3.6 | $5.4M | -55% | 619k | 8.71 |
|
| Phathom Pharmaceuticals (PHAT) | 3.2 | $4.7M | +23% | 445k | 10.62 |
|
| Atyr Pharma Com New (LIFE) | 1.9 | $2.8M | -3% | 1.4M | 1.95 |
|
| Verastem Com New (VSTM) | 1.3 | $2.0M | NEW | 169k | 11.80 |
|
| Gh Research Ordinary Shares (GHRS) | 1.3 | $2.0M | -36% | 186k | 10.66 |
|
| Trevi Therapeutics (TRVI) | 1.2 | $1.7M | -60% | 506k | 3.45 |
|
| Applied Therapeutics (APLT) | 1.0 | $1.5M | NEW | 220k | 6.80 |
|
| Allakos (ALLK) | 0.6 | $968k | +72% | 768k | 1.26 |
|
| Atara Biotherapeutics (ATRA) | 0.4 | $620k | NEW | 893k | 0.69 |
|
Past Filings by Checkpoint Capital
SEC 13F filings are viewable for Checkpoint Capital going back to 2023
- Checkpoint Capital 2024 Q1 filed May 15, 2024
- Checkpoint Capital 2023 Q4 filed Feb. 14, 2024